16th July 2019
ExMateria is an intellectual property law firm protecting your innovations
EX MATERIA (ExM) is an intellectual property law firm, with European and French qualified Partners. ExM deals with intellectual property strategies, including patents, trademarks, designs and any contractual environment linked to this strategy. ExM apply a step by step method to get the most out of the protection and/or defense of your innovations. Our team is composed of dynamic professionals, accustomed to put into practice their energy and expertise to achieve any strategic objectives.
ExM offers legal and technical competencies which are perfectly in line with EIT Health goals. EIT Health members or EIT Health supported entities will benefit from the experience of ExM as being active in the field of start-ups. ExM is a Partner of a Business Angel association like “Investessor” and has developed experiences in helping SMEs and start-ups to build their IP portfolio.
Immersion in R&D is a tool that serves this goal and ExM is highly experienced in this domain. Finally, ExM’s policy is to respond as directly as possible to project needs: our answers are pragmatic, tailored to your profile and designed for the sole purpose of achieving the goal. We do not leave room for the superfluous.
- Help entities to develop and secure their business using the “IP tools”
- Being part of projects that improve care of patients
- Develop a European customer base for ExM
- Increase ExM turnover
- Increase ExM’s number of customers
ExM wants to diversify the technical fields and to benefit from a European visibility. Being part of the EIT Health Network will also provide ExM a high level of credibility in the heath domain, especially medical devices, connected devices, and digital activities related to health. Furthermore, EIT Health can help ExM to acquire long-term relations with new customers.
Click here to learn more about ExM.
For further enquiries contact:
Albane Pariset, email@example.com
NALA.care joins forces with La Roche-Posay
Discover how the partnership will benefit patients
Leuko closes €5M Series A round
Learn more about Leuko and its achievements
EIT Health appoints three new Supervisory Board members
Join us in welcoming our new Board members